Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 3:31 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–4 of 4 matching trials from the live ClinicalTrials.gov search.
Completed Phase 2Phase 3 Interventional Results available

Cocaine Use Reduction With Buprenorphine

NCT01402492
Conditions
Cocaine Dependence
Interventions
Buprenorphine + Naltrexone, Placebo + Naltrexone
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 65 Years
Enrollment
302 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
11
States / cities
Los Angeles, California • San Francisco, California • Denver, Colorado + 8 more
Conditions
Methamphetamine-dependence, Methamphetamine Abuse
Interventions
extended-release naltrexone (XR-NTX), extended release bupropion (BUP-XL) tablets (BUP-XL), iPLB, oPLB
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 65 Years
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
11
States / cities
Little Rock, Arkansas • Los Angeles, California • San Diego, California + 8 more
Conditions
Methamphetamine Use Disorder
Interventions
Naltrexone: Vivitrol®, Placebo (PLB) Injectable, Bupropion: Wellbutrin XL®, Placebo (PLB) Oral
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
403 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
8
States / cities
Los Angeles, California • San Francisco, California • Minneapolis, Minnesota + 5 more
Conditions
Cocaine Use Disorder
Interventions
Extended-Release Naltrexone, Extended Release Buprenorphine, Placebo (PLB) Injectable matched to XR-NTX, Placebo (PLB) Injectable matched to XR-BUP
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
427 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
12
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 8 more